<DOC>
	<DOCNO>NCT01655056</DOCNO>
	<brief_summary>The study aim investigate effect YM150 compare gender ethnic difference healthy Caucasian Japanese male female subject .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability YM150 Healthy Caucasian Japanese Male Female Subjects , Assess Effect That Gender May Have Its Actions Body</brief_title>
	<detailed_description>Each dose group consist cohort 8 Caucasian 8 Japanese male subject randomize 6 subject race receive active treatment 2 subject race receive match placebo . The high tolerated dose repeat cohort 8 Caucasian 8 Japanese female subject , unless emerge safety PK information justifies higher dose level require additional female dose group . Each subject administer single dose YM150 placebo Day 1 follow multiple dos YM150 placebo daily Days 3 9 .</detailed_description>
	<mesh_term>Darexaban</mesh_term>
	<criteria>Japanese subject bear Japan , Japanese parent , Japanese passport , resident West longer 10 year Japanese lifestyle ( food habit ) Caucasian subject : Body weight : Males : 60100 kg Females : 5090 kg BMI : 18.027.0 kg/m2 ( male female ) Japanese subject : Body weight : Males : 5080 kg Females : 4070 kg BMI : 18.027.0 kg/m2 ( male female ) Female subject childbearing potential , practice adequate method prevent pregnancy , like abstinence double barrier method ( e.g . condom combination spermicidal cr√®me ) Female subject show positive pregnancy test Lactating mother woman intention pregnancy Known suspect hypersensitivity YM150 constituent formulation use History and/or sign symptom indicate current abnormal hemostasis blood dyscrasia , include limited neutropenia , thrombocytopenia , thrombocytopathy , thromboasthenia , hemophilia , Von Willebrand 's disease , vascular purpura , bleed gum , frequent nose bleed Family history congenital vascular malformation ( e.g . Marfan 's Syndrome ) and/or bleed disorder ( e.g . hemophilia , Von Willebrand 's disease , Christmas disease ) History peptic ulcer organic lesion susceptible bleed PT aPTT screen visit outside normal range Any surgical intervention ( include tooth extraction ) trauma within last 3 month precede initiation study Any clinically significant history asthma , eczema , clinically significant allergic condition previous severe hypersensitivity drug Any clinically significant upper gastrointestinal symptom likely interfere absorption drug History presence cardiovascular disease disorder History clinically significant ECG abnormality Any clinically relevant history disease disorder gastrointestinal , respiratory , renal , hepatic , neurological , dermatological , psychiatric metabolic Any clinically significant abnormality follow investigator 's review prestudy physical examination , ECG , clinical laboratory test Abnormal heart rate blood pressure measurement screen visit follow : heart rate &lt; 40 &gt; 90 bpm ; mean systolic blood pressure &lt; 95 &gt; 160 mmHg ; mean diastolic blood pressure &lt; 40 &gt; 95 mmHg ( blood pressure measurement take triplicate subject rest supine position 5 min ) Regular use prescribe OTC drug 4 week prior admission clinical unit OR use drug 2 week prior admission clinical unit History drug abuse time , OR use drug abuse within 3 month prior admission clinical unit Participation clinical study within 3 month , participation 3 clinical study within 12 month , prior expect date enrolment study History drink 21 unit alcohol per week ( 1 unit = 270 ml beer 40 ml spirit 125 ml wine ) within 3 month prior admission clinical unit History smoking 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission clinical unit Subject , antiHAV ( IgM ) , antiHCV , HBsAg HIV1 2 positive Donation blood ( &gt; 400 ml ) blood product within 3 month prior admission clinical unit plasmapheresis within 4 week prior admission clinical unit Employees Astellas Group CRO involve study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Phase 1</keyword>
	<keyword>YM150</keyword>
	<keyword>Dose-escalating</keyword>
	<keyword>Ethnicity</keyword>
	<keyword>Caucasian</keyword>
	<keyword>Japanese</keyword>
</DOC>